[HTML][HTML] ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
Current and future perspectives of liquid biopsies in genomics-driven oncology
Precision oncology seeks to leverage molecular information about cancer to improve patient
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …
Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib
GR Oxnard, Y Hu, KF Mileham, H Husain… - JAMA …, 2018 - jamanetwork.com
Importance Osimertinib mesylate is used globally to treatEGFR-mutant non–small cell lung
cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by theEGFRT790M …
cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by theEGFRT790M …
Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review
Purpose.—Clinical use of analytical tests to assess genomic variants in circulating tumor
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …
[HTML][HTML] The emerging role of cell-free DNA as a molecular marker for cancer management
AJ Bronkhorst, V Ungerer, S Holdenrieder - Biomolecular detection and …, 2019 - Elsevier
An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …
Integrating liquid biopsies into the management of cancer
During cancer progression and treatment, multiple subclonal populations of tumour cells
compete with one another, with selective pressures leading to the emergence of …
compete with one another, with selective pressures leading to the emergence of …
[HTML][HTML] Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular cancer, 2018 - Springer
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
[HTML][HTML] Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC
The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …
considerable potential to improve clinical outcomes across multiple cancer types, including …